M
Markus Warmuth
Researcher at Novartis
Publications - 85
Citations - 15520
Markus Warmuth is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & RNA splicing. The author has an hindex of 41, co-authored 85 publications receiving 13214 citations. Previous affiliations of Markus Warmuth include Ludwig Maximilian University of Munich & Genomics Institute of the Novartis Research Foundation.
Papers
More filters
Journal ArticleDOI
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina,Giordano Caponigro,Nicolas Stransky,Kavitha Venkatesan,Adam A. Margolin,Adam A. Margolin,Sungjoon Kim,Christine D. Wilson,Joseph Lehar,Gregory V. Kryukov,Dmitriy Sonkin,Anupama Reddy,Manway Liu,Lauren Murray,Michael F. Berger,Michael F. Berger,John Monahan,Paula Morais,Jodi Meltzer,Adam Korejwa,Judit Jané-Valbuena,Judit Jané-Valbuena,Felipa A. Mapa,Joseph Thibault,Eva Bric-Furlong,Pichai Raman,Aaron Shipway,Ingo H. Engels,Jill Cheng,Guoying K. Yu,Jianjun Yu,Peter Aspesi,Melanie de Silva,Kalpana Jagtap,Michael D. Jones,Li Wang,Charlie Hatton,Emanuele Palescandolo,Supriya Gupta,Scott Mahan,Carrie Sougnez,Robert C. Onofrio,Ted Liefeld,Laura E. MacConaill,Wendy Winckler,Michael R. Reich,Nanxin Li,Jill P. Mesirov,Stacey Gabriel,Gad Getz,Kristin G. Ardlie,Vivien W. Chan,Vic E. Myer,Barbara L. Weber,Jeffrey A. Porter,Markus Warmuth,Peter Finan,Jennifer L. Harris,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Michael Morrissey,William R. Sellers,Robert Schlegel,Levi A. Garraway,Levi A. Garraway +65 more
TL;DR: The results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents and the generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of ‘personalized’ therapeutic regimens.
Journal ArticleDOI
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen,Matthew J. LaMarche,Ho Man Chan,Peter Fekkes,Jorge Garcia-Fortanet,Michael G. Acker,Brandon Antonakos,Chen Christine Hiu-Tung,Zhouliang Chen,Vesselina G. Cooke,Jason R. Dobson,Zhan Deng,Feng Fei,Brant Firestone,Michelle Fodor,Cary Fridrich,Hui Gao,Denise Grunenfelder,Huaixiang Hao,Jaison Jacob,Samuel B. Ho,Kathy Hsiao,Zhao B. Kang,Rajesh Karki,Mitsunori Kato,Jay Larrow,Laura R. La Bonte,Francois Lenoir,Gang Liu,Shumei Liu,Dyuti Majumdar,Matthew J. Meyer,Palermo Mark G,Lawrence Blas Perez,Minying Pu,Edmund Price,Christopher Quinn,Subarna Shakya,Michael Shultz,Joanna Slisz,Kavitha Venkatesan,Ping Wang,Markus Warmuth,Sarah Williams,Guizhi Yang,Jing Yuan,Ji-Hu Zhang,Ping Zhu,Timothy Michael Ramsey,Nicholas Keen,William R. Sellers,Travis Stams,Pascal D. Fortin +52 more
TL;DR: The discovery of a highly potent (IC50 = 0.071 μM), selective and orally bioavailable small-molecule SHP2 inhibitor, SHP099, that stabilizes SHp2 in an auto-inhibited conformation demonstrates that pharmacological inhibition of SHP1 is a valid therapeutic approach for the treatment of cancers.
Journal ArticleDOI
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici,Juliet Williams,Michael Morrissey,Anlai Wang,Ribo Guo,Anthony Vattay,Kathy Hsiao,Jing Yuan,John Green,Beatriz Ospina,Qunyan Yu,Lance Ostrom,Paul Fordjour,Dustin L. Anderson,John Monahan,Joseph Kelleher,Stefan Peukert,Shifeng Pan,Xu Wu,Sauveur Michel Maira,Carlos Garcia-Echeverria,Kimberly J. Briggs,D. Neil Watkins,Yung Mae Yao,Christoph Lengauer,Markus Warmuth,William R. Sellers,Marion Dorsch +27 more
TL;DR: By identifying a drug combination that delays or even combats development of resistance when used as a first-line treatment in clinical trials, these results could ultimately improve the lives of patients with medulloblastoma or other cancers that depend on Smo for their survival.
Journal ArticleDOI
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang,Francisco Adrian,Wolfgang Jahnke,Sandra W. Cowan-Jacob,Allen G. Li,Roxana E. Iacob,Taebo Sim,Taebo Sim,John T. Powers,John T. Powers,Christine Dierks,Fangxian Sun,Gui Rong Guo,Qiang Ding,Barun Okram,Yongmun Choi,Amy Wojciechowski,Xianming Deng,Guoxun Liu,Gabriele Fendrich,André Strauss,Navratna Vajpai,Stephan Grzesiek,Tove Tuntland,Yi Liu,Badry Bursulaya,Mohammad Azam,Mohammad Azam,Paul W. Manley,John R. Engen,George Q. Daley,George Q. Daley,Markus Warmuth,Nathanael S. Gray +33 more
TL;DR: The results show that therapeutically relevant inhibition of Bcr–Abl activity can be achieved with inhibitors that bind to the myristate-binding site and that combining allosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.
Journal ArticleDOI
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Christine Dierks,Christine Dierks,Ronak Beigi,Gui-Rong Guo,Katja Zirlik,Mario R. Stegert,Paul W. Manley,Christopher Trussell,Annette Schmitt-Graeff,Klemens Landwerlin,Hendrik Veelken,Markus Warmuth,Markus Warmuth +12 more
TL;DR: It is shown that Hedgehog signaling is activated in LSCs through upregulation of Smo, and this indicates that Smo inhibition might be an effective treatment strategy to reduce the LSC pool in CML.